𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy

✍ Scribed by P. Gouveris; A. C. Lazaris; T. G. Papathomas; A. Nonni; V. Kyriakou; J. Delladetsima; E. S. Patsouris; N. Tsavaris

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
280 KB
Volume
133
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topoisomerase-I, thymidylate synthase pr
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients
✍ Angelo Paradiso; JanMing Xu; Anita Mangia; Annalisa Chiriatti; Gianni Simone; Al 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 229 KB

## Abstract While several studies have reported that thymidylate synthase (TS) tumour expression can be a reliable predictive marker of clinical response to 5‐Fluorouracil (5‐FU) for advanced colorectal cancer patients, only a few studies that searched for predictive factors of irinotecan (CPT‐11)

Expression of p21WAF1in Astler–Coller st
Expression of p21WAF1in Astler–Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy
✍ Violetta Sulzyc-Bielicka; Pawel Domagala; Elzbieta Urasinska; Dariusz Bielicki; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 575 KB

In several, but not all, previous studies, positive p21^WAF1^ expression has been suggested as an indicator of a good prognosis in patients with stage III/IV colorectal cancer. However, it is not known whether the same is true for stage B2 patients. The purpose of this study is to assess the influen

Molecular determinants of efficacy for 5
Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes
✍ Bengt Gustavsson; Christopher Kaiser; Göran Carlsson; Yvonne Wettergren; Elisabe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 112 KB 👁 1 views

## Abstract 5‐Fluorouracil (5‐FU)‐based regimens remain a cornerstone in the treatment of colorectal cancer (CRC). However, the attendant toxicity prevents these regimens from reaching maximum therapeutic potential. In this retrospective analysis, we examined the pretreatment expression of 18 genes